Table 6.
Cox proportional hazard models for time to progression in individuals with NC or MCI
| Model 1: no covariates | Model 2: + sex, age, education | Model 3: model 2 + amyloid status | Model 4: model 3 + diagnosis | Model 5: model 4+ APOE-e4 carriership | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95%CI) | p | HR (95%CI) sex, age, edu | p | HR (95%CI) sex, age, edu, abeta | p | HR (95%CI) sex, age, edu, abeta, diagnosis | p | HR (95%CI) sex, age, edu, abeta, diagnosis, APOE-e4 | p | ||
| T-tau subgroups | |||||||||||
| Subgroup 1 | All | Reference | |||||||||
| Subgroup 2 | ADC: Innotest | 6.3 (4.3, 9.2) | 5.79E−21 | 6 (3.9, 9.2) | 1.32E−16 | 3.4 (2.2, 5.3) | 5.96E−08 | 3.4 (2.1, 5.3) | 1.08E−07 | 3.3 (2.1, 5.3) | 4.31E−07 |
| ADNI: Luminex | 2.1 (1.4, 3) | 8.76E−05 | 2 (1.4, 3) | 1.58E−04 | 1.7 (1.2, 2.5) | 5.84E−03 | 1.6 (1.1, 2.4) | 1.24E−02 | 1.5 (1, 2.2) | 2.98E−02 | |
| ADNI: Elecsys | 1.9 (1.3, 2.8) | 9.27E−04 | 1.8 (1.2, 2.7) | 2.44E−03 | 1.8 (1.2, 2.7) | 2.56E−03 | 1.8 (1.2, 2.6) | 3.71E−03 | 1.7 (1.1, 2.5) | 9.74E−03 | |
| Subgroup 3 | ADC: Innotest | 14.6 (9.8, 21.8) | 6.14E−39 | 13.2 (8.3, 20.8) | 3.31E−28 | 6.2 (3.8, 10) | 1.96E−13 | 6.0 (3.7, 9.8) | 6.96E−13 | 6.1 (3.7, 10.1) | 1.86E−12 |
| ADNI: Luminex | 5.2 (3.6, 7.6) | 1.31E−18 | 4.9 (3.4, 7.2) | 3.53E−17 | 2.8 (1.9, 4.1) | 2.86E−07 | 2.6 (1.8, 3.9) | 1.57E−06 | 2.4 (1.6, 3.6) | 1.06E−05 | |
| ADNI: Elecsys | 4.4 (3, 6.4) | 6.15E−14 | 4 (2.7, 5.9) | 2.05E−12 | 3.1 (2.1, 4.5) | 1.88E−08 | 2.8 (1.9, 4.2) | 1.91E−07 | 2.7 (1.8, 4) | 1.60E−06 | |
| Subgroup 4 | ADC: Innotest | 21.3 (7.5, 60.6) | 9.81E−09 | 15 (4.4, 50.9) | 1.43E−05 | 6.5 (1.9, 22.3) | 2.93E−03 | 6.6 (1.9, 22.7) | 2.70E−03 | 6.4 (1.9, 22.2) | 3.30E−03 |
| ADNI: Luminex | 6.7 (4.2, 10.7) | 1.01E−15 | 6.6 (4.1, 10.6) | 3.89E−15 | 3.4 (2.1, 5.6) | 8.31E−07 | 2.8 (1.7, 4.5) | 6.50E−05 | 2.6 (1.5, 4.2) | 2.63E−04 | |
| ADNI: Elecsys | 7.1 (4.3, 11.7) | 2.96E−14 | 7.2 (4.3, 12) | 2.37E−14 | 4.6 (2.7, 7.7) | 6.71E−09 | 3.9 (2.3, 6.6) | 2.99E−07 | 3.5 (2.1, 6.1) | 3.59E−06 | |
| P-tau subgroups | |||||||||||
| Subgroup 1 | All | Reference | |||||||||
| Subgroup 2 | ADC: Innotest | 4.4 (3.1, 6.2) | 4.13E−17 | 3.9 (2.7, 5.7) | 2.35E−12 | 2.1 (1.4, 3.2) | 1.71E−04 | 2.1 (1.4, 3.1) | 2.28E−04 | 2.1 (1.4, 3.2) | 4.88E−04 |
| ADNI: Luminex | 2.2 (1.5, 3) | 7.78E−06 | 2.1 (1.5, 3) | 1.38E−05 | 1.5 (1.0, 2.1) | 3.30E−02 | 1.4 (1.0, 2.0) | 5.85E−02 | 1.4 (1, 2) | 7.19E−02 | |
| ADNI: Elecsys | 2.6 (1.9, 3.6) | 9.65E−10 | 2.6 (1.9, 3.5) | 3.83E−09 | 2.2 (1.6, 3.0) | 1.73E−06 | 2.0 (1.5, 2.8) | 1.22E−05 | 2 (1.4, 2.7) | 4.34E−05 | |
| Subgroup 3 | ADC: Innotest | 10.2 (7, 14.8) | 1.48E−33 | 8.4 (5.6, 12.8) | 1.10E−23 | 3.7 (2.4, 5.8) | 6.58E−09 | 3.6 (2.3, 5.6) | 2.03E−08 | 3.5 (2.2, 5.6) | 1.02E−07 |
| ADNI: Luminex | 4.4 (3.1, 6.3) | 1.81E−16 | 4.3 (3.0, 6.2) | 4.37E−16 | 2.3 (1.6, 3.3) | 1.80E−05 | 2.2 (1.5, 3.2) | 7.21E−05 | 2 (1.4, 3) | 2.88E−04 | |
| ADNI: Elecsys | 5.0 (3.6, 7.1) | 7.09E−20 | 4.7 (3.3, 6.7) | 4.35E−18 | 3.0 (2.1, 4.3) | 4.19E−09 | 2.7 (1.9, 3.9) | 1.32E−07 | 2.6 (1.8, 3.7) | 8.22E−07 | |
| Subgroup 4 | ADC: Innotest | 9.5 (3.4, 26.5) | 1.69E−05 | 4.6 (1.4, 15.5) | 1.28E−02 | 2.1 (0.6, 7.2) | 2.19E−01 | 2.1 (0.6, 7.1) | 2.29E−01 | 4 (1.2, 13.8) | 2.72E−02 |
| ADNI: Luminex | 5.0 (2.4, 10.6) | 2.83E−05 | 5.8 (2.7, 12.4) | 5.32E−06 | 2.5 (1.2, 5.5) | 1.76E−02 | 2.3 (1.0, 4.9) | 3.81E−02 | 2.1 (0.9, 4.5) | 6.85E−02 | |
| ADNI: Elecsys | 7.7 (4.7, 12.6) | 3.47E−16 | 8.2 (4.9, 13.4) | 1.24E−16 | 4.7 (2.8, 7.7) | 3.52E−09 | 3.9 (2.3, 6.6) | 2.51E−07 | 3.6 (2.1, 6.1) | 2.11E−06 | |
| Amyloid status | |||||||||||
| Amyloid abnormal | ADC: Innotest (< 813 pg/ml)1 | 10.8 (7.3, 15.9) | 8.71E−33 | 8.9 (5.9, 13.4) | 6.65E−25 | n.t. | 7.8 (5.0, 12.0) | 1.88E−20 | 7.2 (4.5, 11.5) | 5.27E−17 | |
| ADNI: Luminex (< 192 pg/ml)2 | 5.2 (3.8, 7.0) | 2.29E−25 | 5.0 (3.6, 6.8) | 4.91E−24 | n.t. | 4.4 (3.2, 6.0) | 1.79E−20 | 3.8 (2.7, 5.3) | 4.16E−15 | ||
| ADNI: Elecsys (< 880 pg/ml)3 | 4.2 (3.2, 5.5) | 1.60E−26 | 4.1 (3.1, 5.3) | 8.27E−25 | n.t. | 3.5 (2.7, 4.6) | 1.30E−19 | 3 (2.2, 4) | 2.51E−13 | ||
| Continuous predictors | |||||||||||
| Continuous ab1-42 (z score; HR per SD) | ADC: Innotest | 0.3 (0.2, 0.4) | 3.31E−36 | 0.3 (0.3, 0.4) | 8.16E−27 | 0.6 (0.4, 0.8) | 2.84E−03 | 0.6 (0.4,0.9) | 4.17E−03 | 0.6 (0.4, 0.8) | 4.75E−03 |
| ADNI: Luminex | 0.5 (0.4, 0.5) | 1.71E−30 | 0.5 (0.4, 0.5) | 6.62E−23 | 0.6 (0.5, 0.8) | 7.12E−05 | 0.7 (0.5, 0.9) | 2.19E−03 | 0.7 (0.6, 0.9) | 1.79E−02 | |
| ADNI: Elecsys | 0.4 (0.3, 0.5) | 2.24E−23 | 0.4 (0.3, 0.5) | 7.05E−22 | 0.6 (0.4, 0.8) | 1.14E−04 | 0.6 (0.5,0.8) | 1.56E−04 | 0.6 (0.5, 0.8) | 5.41E−04 | |
| Continuous t-tau (z score; HR per SD) | ADC: Innotest | 1.6 (1.5, 1.7) | 7.67E−58 | 1.9 (1.7, 2.1) | 3.60E−32 | 1.5 (1.3, 1.7) | 2.42E−11 | 1.5 (1.3, 1.7) | 4.57E−11 | 1.6 (1.4, 1.8) | 3.46E−11 |
| ADNI: Luminex | 1.7 (1.6, 1.9) | 7.95E−32 | 1.7 (1.6, 1.9) | 5.61E−31 | 1.4 (1.3, 1.6) | 1.80E−11 | 1.4 (1.2, 1.5) | 1.15E−08 | 1.3 (1.2, 1.5) | 1.69E−07 | |
| ADNI: Elecsys | 1.6 (1.5, 1.8) | 8.36E−27 | 1.7 (1.5, 1.8) | 1.39E−25 | 1.4 (1.3, 1.6) | 2.41E−13 | 1.4 (1.3, 1.5) | 1.51E−10 | 1.4 (1.2, 1.5) | 4.90E−09 | |
| Continuous p-tau (z score; HR per SD) | ADC: Innotest | 1.8 (1.7, 2.0) | 2.92E−42 | 1.7 (1.5, 1.9) | 3.31E−22 | 1.4 (1.2, 1.6) | 1.11E−07 | 1.4 (1.2, 1.6) | 3.56E−07 | 1.5 (1.3, 1.7) | 3.03E−08 |
| ADNI: Luminex | 1.5 (1.4, 1.6) | 5.58E−24 | 1.6 (1.4, 1.7) | 1.75E−25 | 1.3 (1.2, 1.5) | 1.67E−08 | 1.3 (1.2, 1.4) | 2.46E−07 | 1.3 (1.1, 1.4) | 4.28E−06 | |
| ADNI: Elecsys | 1.7 (1.5, 1.8) | 3.36E−31 | 1.7 (1.5, 1.9) | 1.06E−29 | 1.5 (1.3, 1.6) | 1.72E−13 | 1.4 (1.3, 1.5) | 9.62E−11 | 1.4 (1.2, 1.5) | 3.05E−09 | |
N.t. not tested
1Source: Tijms BM et al., Clinical Chemistry. 2018;64(3):576–585
2Source: [21]
3Source: Hansson O et al., Alzheimer’s & Dementia. 2018;14(11):1470–1481